NCT02732938 - Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 4, 2016

Primary Completion Date

September 15, 2017

Study Completion Date

October 10, 2017

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

DRUG

PF-04136309

PF-04136309 oral dosing

DRUG

Nab-paclitaxel

Nab-paclitaxel IV dosing

DRUG

Gemcitabine

Gemcitabine IV dosing

Trial Locations (18)

10022

Memorial Sloan Kettering Cancer Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

14642

University of Rochester Cancer Center Pharmacy, Rochester

University of Rochester Medical Center, Rochester

27534

Southeastern Medical Oncology Center, Goldsboro

Wayne Memorial Hospital, Goldsboro

28328

Sampson Regional Medical Center, Clinton

Southeastern Medical Oncology Center, Clinton

28546

Onslow Memorial Hospital, Jacksonville

Southeastern Medical Oncology Center, Jacksonville

29406

MUSC Health North Charleston, North Charleston

29425

Medical University of South Carolina, Charleston

MUSC Hollings Cancer Center, Charleston

29464

MUSC Health East Cooper, Mt. Pleasant

02114

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston